[Fixed-dose combination therapy with rosuvastatin/acetylsalicylic acid in the cardiovascular risk continuum].

The use of polypill, a single pill containing more therapeutic agents, has shown to increase therapeutic adherence and improve cardiovascular prognosis. Among the several polypills currently available, the fixed dose combination of rosuvastatin at different doses and acetylsalicylic acid (ASA) at low dose represents a useful therapeutic option for cardiovascular disease prevention. When the impact of rosuvastatin in association with ASA on cardiovascular disease incidence has been compared with the combination of other statins with ASA, rosuvastatin plus ASA is the combination associated with the lowest incidence of several cardiovascular diseases. As regards the use of ASA in primary prevention, the global clinical benefit may be weakened by the occurrence of bleedings. Therefore, in primary prevention, the combination rosuvastatin/ASA may be considered when the bleeding risk is low and the cardiovascular risk is augmented. In secondary prevention, the need for an early optimal management of cholesterol control may require the use of a fixed dose combination of statin/ezetimibe and ASA in a separate formulation. However, in selected cases in which the distance from the therapeutic low-density lipoprotein cholesterol target does not require the combination of high efficacy statin with ezetimibe, the fixed dose combination rosuvastatin/ASA may be considered even in secondary prevention.